Improvement Through Innovation: How Much Evidence Do You Need to Adopt?

The European Union's novel Medical Device Regulation (EU MDR) has reshaped the landscape of orthopedic device development and adoption. Moving beyond the traditional pathway of CE-marking implants, the regulation places heightened emphasis on clinical evidence and post-market surveillance, significantly impacting how early innovators and late adopters navigate the market. In this keynote, we will explore the interplay of innovation, regulation, and clinical adoption in the context of transformative orthopedic technologies, including robotic surgery, minimally invasive approaches, and next-generation biomaterials. Central to the discussion is the balance between risks, costs, and benefits—key considerations for all stakeholders in an era of rapidly advancing medical technology. Examples of emerging technologies that exemplify this balance include robotic-assisted systems for joint replacement, offering enhanced precision and reduced recovery times, but requiring significant investment and training. Similarly, advanced biomaterials such as bioresorbable scaffolds and patient-specific implants promise improved integration and outcomes but demand robust preclinical and clinical validation. Additive manufacturing, or 3D printing, is another frontier in orthopedic innovation, enabling customized implants and surgical tools that enhance fit and function, yet raising questions about regulatory consistency and quality assurance. However, history reminds us to temper enthusiasm with caution. For instance, the Robodoc surgical system, one of the first robotic platforms introduced in the early 2000s, aimed to revolutionize orthopedic surgery but faced significant challenges, including prolonged surgical times and technical complications, leading to its limited adoption. Similarly, the orthopedic community recalls the widespread adoption of metal-on-metal hip implants, which initially showed promise but later caused significant adverse outcomes, underscoring the importance of rigorous long-term evaluation. This session will provide a comprehensive framework for orthopedic surgeons, researchers, and industry representatives to harmonize innovation with regulation, fostering a patient-centered approach to evaluating and adopting novel medical devices.